183
Participants
Start Date
February 28, 2005
Primary Completion Date
February 28, 2007
Study Completion Date
February 28, 2007
SB497115
SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
Placebo
Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
GSK Investigational Site, Taipei
GSK Investigational Site, Tau-Yuan County
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Sofia
GSK Investigational Site, Budapest
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, La Plata
GSK Investigational Site, Rosario
GSK Investigational Site, Plovdiv
GSK Investigational Site, Székesfehérvár
GSK Investigational Site, New York
GSK Investigational Site, Babylon
GSK Investigational Site, Berlin
GSK Investigational Site, Córdoba
GSK Investigational Site, Newark
GSK Investigational Site, Milan
GSK Investigational Site, Hamburg
GSK Investigational Site, Großhansdorf
GSK Investigational Site, Salem
GSK Investigational Site, Durham
GSK Investigational Site, Madrid
GSK Investigational Site, Savannah
GSK Investigational Site, Hollywood
GSK Investigational Site, Tamarac
GSK Investigational Site, Boca Raton
GSK Investigational Site, Marburg
GSK Investigational Site, Santander
GSK Investigational Site, Santa Cruz de Tenerife
GSK Investigational Site, Tupelo
GSK Investigational Site, Hattiesburg
GSK Investigational Site, Seville
GSK Investigational Site, Mayfield Heights
GSK Investigational Site, Akron
GSK Investigational Site, Dnipro
GSK Investigational Site, Trier
GSK Investigational Site, Minneapolis
GSK Investigational Site, Hemer
GSK Investigational Site, Metairie
GSK Investigational Site, Jonesboro
GSK Investigational Site, Bryan
GSK Investigational Site, Lviv
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Colorado Springs
GSK Investigational Site, Benevento
GSK Investigational Site, Donetsk
GSK Investigational Site, Ogden
GSK Investigational Site, Tucson
GSK Investigational Site, Campobasso
GSK Investigational Site, Las Vegas
GSK Investigational Site, Los Angeles
GSK Investigational Site, Los Angeles
GSK Investigational Site, Long Beach
GSK Investigational Site, Regensburg
GSK Investigational Site, Mérida
GSK Investigational Site, Bad Berka
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Hyderabad, Andhra Pradesh
GSK Investigational Site, Greenbrae
GSK Investigational Site, Baltimore
GSK Investigational Site, Toledo
GSK Investigational Site, Capital Federal
GSK Investigational Site, Rosario
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Vienna
GSK Investigational Site, Vienna
GSK Investigational Site, Vienna
GSK Investigational Site, Brno
GSK Investigational Site, Prague
GSK Investigational Site, Bangalore
GSK Investigational Site, Kolkata
GSK Investigational Site, Vellore
GSK Investigational Site, Rome
GSK Investigational Site, Lima
GSK Investigational Site, Olsztyn
GSK Investigational Site, Poznan
GSK Investigational Site, Poznan
GSK Investigational Site, Szczecin
GSK Investigational Site, Wroclaw
GSK Investigational Site, Bucharest
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow Region
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Kyiv
GSK Investigational Site, Truro
GSK Investigational Site, Chelmsford
GSK Investigational Site, Colchester
GSK Investigational Site, Dundee
GSK Investigational Site, Leicester
Lead Sponsor
GlaxoSmithKline
INDUSTRY